Position in BCYC
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$111,300
+$76,236 QoQ
Shares Held
26,250
+247.4% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#5
of 14 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCYC Over Time
Shares Held
Position Value (USD)
Derivatives in BCYC
reported options exposure · as of Dec 31, 2025CallValue
$1,111
CallShares
157
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $19,945,542 across 57 Biotechnology names. BCYC ranks #18 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NUVL |
Nuvalent, Inc.
|
108,951 | $13,455,448 | |
| 2 | ABVX |
Abivax S.A.
|
7,605 | $1,013,442 | |
| 3 | SGMT |
Sagimet Biosciences Inc.
|
109,250 | $844,502 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
5,000 | $663,650 | |
| 5 | JANX |
Janux Therapeutics, Inc.
|
30,850 | $473,856 | |
| 6 | NKTR |
Nektar Therapeutics
|
5,500 | $383,955 | |
| 7 | VERU |
Veru Inc.
|
105,081 | $328,903 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
8,170 | $318,711 |
All Filings in BCYC
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $111,300 | 26,250 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $35,064 | 7,557 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $1,111 | 157 | Call | Sole | 2026-01-16 | |
| 2025-12-31 | $53,000 | 7,486 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $1,083 | 140 | Call | Sole | 2025-12-15 | |
| 2025-09-30 | $81,270 | 10,500 | Shares | Sole | 2025-12-15 | |
| No filing history on record for this holder in this stock. | ||||||